 

Active ingredient: Alprazolam 

 

Form/Route: Tablet/Oral 

 

Recommended studies: 2 studies 

 

Type of study: Fasting 
Design: Single-dose, two-treatment, two-period crossover in-vivo 

Strength: 1 mg 

Subjects: Normal healthy males and females, general population 

Additional Comments: 

______________________________________________________________________________ 

 

Type of study: Fed 
Design: Single-dose, two-treatment, two-period crossover in-vivo 

Strength: 1 mg 

Subjects: Normal healthy males and females, general population 

Additional Comments: 

______________________________________________________________________________ 

 

Analytes to measure: Alprazolam in plasma 

 

Bioequivalence based on (90% CI): Alprazolam 

 

Waiver request of in-vivo testing: 0.25 mg, 0.5 mg and 2 mg based on (i) acceptable 
bioequivalence studies on the 1 mg strength, (ii) proportional similarity of the formulations 
across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths. 

 

Dissolution test method and sampling times: 

 

Please note that a Dissolution Methods Database is available to the public at the OGD website at 
http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this product at this 
website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test 
and reference products. Specifications will be determined upon review of the application. 

 


